The central problem is that spinal cord injury is not a single event but a cascading catastrophe. The initial mechanical trauma triggers a wave of secondary damage: runaway inflammation, oxidative stress, programmed cell death, excitotoxicity from excessive neurotransmitter signaling, formation of a glial scar that walls off regeneration, and a hostile extracellular environment that blocks axons from regrowing. Each of these processes has become a therapeutic target in its own right, yet traditional drugs struggle to reach the injured tissue at all. The blood-spinal cord barrier, a tight cellular gatekeeper that normally protects neural tissue, also excludes most systemically administered compounds. Drugs that do get through are often cleared rapidly, suffer from short half-lives, and spread into healthy organs where they cause toxic side effects. The result has been a long string of disappointing clinical trials.

Nanocarriers promise to change that calculus by acting as programmable couriers. The review systematically compares the major delivery platforms developed over the past ten years, including liposomes, polymeric nanoparticles, micelles, inorganic nanomaterials, nanozymes, exosomes, biomimetic carriers, nanohydrogels, and composite scaffolds. Each platform occupies a distinct niche. Liposomes, spherical vesicles built from lipid bilayers, can encapsulate both water-soluble and fat-soluble drugs and shield them from premature degradation. Polymeric nanoparticles offer tunable release kinetics, allowing a therapeutic payload to be dispensed over days or weeks rather than in a single burst. Micelles, self-assembled from amphiphilic molecules, excel at solubilizing hydrophobic drugs that would otherwise be unusable. Inorganic nanomaterials bring unique physical properties, such as magnetic guidance or imaging capability, that enable simultaneous diagnosis and treatment.

Two platforms stand out in the review for their preclinical promise: biomimetic carriers and multifunctional nanozymes. Biomimetic carriers take inspiration from nature by cloaking synthetic nanoparticles in cell-derived membranes, such as those from platelets, macrophages, or stem cells. This camouflage exploits the body’s own trafficking signals, allowing the particles to cross biological barriers, evade immune clearance, and home in on inflamed tissue with far greater precision than bare synthetic particles. In the context of spinal cord injury, where the injury microenvironment is saturated with activated immune cells, such biomimetic targeting can concentrate drugs exactly where secondary damage is unfolding. Nanozymes, meanwhile, are engineered nanomaterials that mimic the catalytic activity of natural enzymes. Multifunctional nanozymes can scavenge the reactive oxygen species that drive oxidative stress while simultaneously delivering neuroprotective drugs, effectively combining a therapeutic agent and a delivery vehicle in a single construct.

The review organizes therapeutic effects around seven major mechanisms, providing a framework that researchers can use to match carrier design to pathological need. The first is inhibition of inflammation, particularly through the regulation of macrophage and microglia polarization. After injury, these immune cells can adopt pro-inflammatory states that amplify tissue destruction or anti-inflammatory states that promote repair. Nanocarriers carrying polarizing agents can push this balance toward recovery. The second mechanism is antagonism of oxidative stress, where antioxidant payloads and nanozymes neutralize the free radicals that damage neurons and oligodendrocytes in the hours and days following trauma.

The third and fourth mechanisms involve regulation of programmed cell death and neuroprotection, and the promotion of axonal regeneration alongside myelin repair. Apoptosis and related forms of controlled cell death claim many neurons that survive the initial impact, so nanocarriers that deliver anti-apoptotic agents directly to endangered cells can preserve functional circuitry. Once cell survival is secured, the challenge shifts to rebuilding connections. Axons must regrow through damaged tissue, and the myelin sheaths that insulate them must be restored for signals to travel efficiently. Nanocarriers have been used to deliver growth-promoting factors and inhibitors of myelin-associated repulsive molecules, creating a permissive environment for regeneration.

The remaining mechanisms address the structural aftermath of injury. Glial scar and extracellular matrix remodeling target the dense meshwork of proteins and glial processes that physically blocks regenerating axons; nanotherapies can soften or reorganize this barrier rather than simply trying to push axons through it. Finally, vascular repair and blood-spinal cord barrier reconstruction recognize that recovery of the injury site’s blood supply and the restoration of barrier integrity are prerequisites for lasting functional improvement. Nanocarriers delivering angiogenic factors or barrier-stabilizing compounds address this vascular dimension, which earlier therapeutic strategies often neglected.

Beyond soluble drug delivery, the review highlights biomaterials that provide physical support to the injured cord. Nanohydrogels and composite scaffolds can be injected or implanted into the lesion cavity, where they serve double duty as drug depots and as three-dimensional substrates that guide growing axons. These materials can be engineered to degrade at controlled rates, releasing their payloads in sync with the temporal phases of secondary injury, from the acute inflammatory storm to the chronic scarring stage. This stage-matched delivery is a recurring theme in the review’s analytical framework: the authors argue that rational nanomedicine design should integrate carrier characteristics with the specific pathological mechanisms dominant at each phase of injury, rather than treating spinal cord injury as a uniform target.

Despite the enthusiasm, the review is candid about the bottlenecks standing between laboratory success and clinical reality. Long-term safety validation remains insufficient for most platforms, a serious concern for materials that may persist in neural tissue. Targeting efficiency is often low, meaning that only a fraction of an administered dose reaches the injury site. Significant discrepancies between animal models and human clinical pathology complicate the interpretation of preclinical results, since rodent contusion injuries do not fully recapitulate the heterogeneity of human trauma. Scaling up nanoparticle preparation from bench-top synthesis to reproducible, pharmaceutical-grade manufacturing poses its own engineering and regulatory challenges. These hurdles explain why, despite promising preclinical data, no nanocarrier therapy for spinal cord injury has yet completed successful clinical translation.

Looking forward, the authors identify several directions that could accelerate progress. Microenvironment-responsive smart delivery systems, which release their payloads only when triggered by the acidity, enzyme activity, or oxidative conditions characteristic of injured tissue, could dramatically improve specificity and reduce side effects. The integration of nanotechnology with stem cell therapy and neuromodulation strategies could combine regenerative cell sources with precisely timed molecular support and electrical stimulation. Perhaps most importantly, the establishment of standardized evaluation systems across laboratories would make it possible to compare platforms fairly and build the robust safety and efficacy datasets that regulators require. If those pieces come together, the mechanism-driven framework laid out in this review could serve as the blueprint for turning a decade of nanocarrier innovation into the first effective treatments for a condition that medicine has long considered untreatable.

Subject of Research: Nanocarrier-based targeted drug delivery for spinal cord injury treatment

Article Title: Smart nanocarriers and biomaterials for targeted drug delivery in spinal cord injury: molecular mechanisms and translational perspectives

Article References: Han, W., Qi, P., Li, J., Min, L., Li, H., & Yin, H. (2026). Smart nanocarriers and biomaterials for targeted drug delivery in spinal cord injury: molecular mechanisms and translational perspectives. Frontiers in Bioengineering and Biotechnology, 14, Article 1973263. https://doi.org/10.3389/fbioe.2026.1973263

Image Credits: AI Generated

DOI: 10.3389/fbioe.2026.1973263

Keywords: spinal cord injury, nanocarriers, drug delivery, biomimetic carriers, nanozymes, blood-spinal cord barrier, glial scar, axonal regeneration, liposomes, exosomes, nanohydrogels, neuroprotection